ZEDENOLEUCEL

UNII:	L4D9X59F34
Formula:
Preferred Substance Name:	ZEDENOLEUCEL
GSRS Full Record:	L4D9X59F34 i

MT-401
MULTI-TUMOR-ASSOCIATED ANTIGEN (TAA) SPECIFIC T LYMPHOCYTES. THE MANUFACTURING PROCESS SELECTIVELY AMPLIFIES TUMORTARGETED T CELL PRECURSORS EX VIVO USING ANTIGEN PRESENTING CELLS (APCS) EXPRESSING A RANGE OF TAAS THAT ARE SELECTIVELY OVEREXPRESSED ON LEUKEMIC CELLS. THE STIMULATION IS PERFORMED USING ASEPTIC METHODS AND CLINICAL GRADE PEPTIDE MIXTURES. DONOR T CELLS ARE CULTURED WITH AUTOLOGOUS APCS LOADED WITH THE PEPTIDE MIXTURES SPANNING THE ENTIRE PRIMARY SEQUENCES OF THE FOUR TUMOR ASSOCIATED ANTIGENS PRAME, NY-ESO-1, SURVIVIN, AND WT1 IN THE PRESENCE OF RECOMBINANT CYTOKINES TO STIMULATE T CELL GROWTH
ZEDENOLEUCEL [INN]
ZEDENOLEUCEL [USAN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ZEDENOLEUCEL

Synonyms and Mappings

Resources